ATLAS / Macro Radar / Reporting / AEON

AEON Biopharma, Inc. (AEON) reporting calendar

AEON Biopharma, Inc. files periodic reports with the SEC as AEON on NYSE. Atlas tracks 22 filed reports for this issuer, each linked to its original EDGAR accession.

Next window
21 Jul 2026 – 5 Sep 2026
Latest report
10-Q
Period ended
31 Mar 2026
Filed
14 May 2026
Reports on record
22

How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 44 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.

Filed periodic reports

FormPeriod endedFiledLagSEC accession
10-Q31 Mar 202614 May 202644 days0001837607-26-000042
10-K31 Dec 202530 Mar 202689 days0001837607-26-000019
10-Q30 Sep 202514 Nov 202545 days0001837607-25-000085
10-Q30 Jun 202512 Aug 202543 days0001837607-25-000066
10-Q31 Mar 202514 May 202544 days0001837607-25-000050
10-K31 Dec 202424 Mar 202583 days0001837607-25-000022
10-Q30 Sep 202413 Nov 202444 days0001837607-24-000093
10-Q30 Jun 202412 Aug 202443 days0001558370-24-011896
10-Q31 Mar 202414 May 202444 days0001837607-24-000063
10-K31 Dec 202329 Mar 202489 days0001837607-24-000015
10-Q30 Sep 202313 Nov 202344 days0001558370-23-018706
10-Q30 Jun 202321 Jul 202321 days0001104659-23-082959
10-Q31 Mar 202317 May 202347 days0001104659-23-061821
10-K31 Dec 202222 Feb 202353 days0001104659-23-023947
10-Q30 Sep 202214 Nov 202245 days0001104659-22-117341
10-Q30 Jun 202212 Aug 202243 days0001104659-22-090142
10-Q31 Mar 202212 May 202242 days0001104659-22-059538
10-K31 Dec 202128 Mar 202287 days0001104659-22-038759
10-Q30 Sep 202115 Nov 202146 days0001104659-21-138543
10-Q30 Jun 202116 Aug 202147 days0001104659-21-105386
10-Q31 Mar 202115 Jun 202176 days0001104659-21-081012
10-K31 Dec 202031 Mar 202190 days0001104659-21-044781

Source: SEC EDGAR company submissions for CIK 0001837607. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.